论文部分内容阅读
目的 探讨黄杆菌致下呼吸道感染的危险因素及其耐药性的分布情况。方法 分析2 6例黄杆菌致下呼吸道感染的临床资料 ,采用平板稀释法测定常用抗菌药物对该株菌的最低抑菌浓度 (MIC)。结果 2 6例中 >6 0岁者 15例 (5 8% ) ,全部病例均有基础疾病 ,其中以恶性肿瘤最常见(31% )。 5 0 %病例为混合感染。发病的危险因素为 :广谱抗菌药物的应用 (81% ) ;机体的免疫抑制(77% ) ;侵袭性治疗 (31% ) ;长期住院。临床症状及X线表现无特异性。耐药率高 ,众多常用药物中 ,仅有环丙沙星、复方磺胺甲唑 (复方新诺明 )及哌拉西林耐药率低于 40 %。结论 黄杆菌致下呼吸道感染多发生于患有各种基础疾病、免疫功能低下及长期应用广谱抗菌药物者 ,临床表现无特异性 ,细菌的耐药现象严重 ,诊断及治疗有赖于病原学检查
Objective To investigate the risk factors and drug resistance distribution of lower respiratory tract infection caused by Flavobacterium. Methods The clinical data of 26 cases of lower respiratory tract infection caused by Flavobacterium were analyzed. The minimum inhibitory concentration (MIC) of the commonly used antibacterial drugs against this strain of bacteria was determined by the plate dilution method. Results Of the 26 cases, 15 (58%) were over 60 years old. All cases had underlying diseases, of which malignant tumors were the most common (31%). Fifty percent of cases were mixed infections. The risk factors for the disease were: broad-spectrum antimicrobial use (81%); immunosuppression in the body (77%); invasive treatment (31%); long-term hospitalization. Clinical symptoms and X-ray showed no specificity. Among the many commonly used drugs, only ciprofloxacin, sulfamethoxazole (cotrimoxazole) and piperacillin were less than 40%. Conclusion Bacillus flavus-induced lower respiratory tract infections occur in patients with a variety of underlying diseases, immunocompromise and long-term use of broad-spectrum antimicrobial agents, nonspecific clinical manifestations, bacterial resistance is serious, diagnosis and treatment depends on etiological examination